Join
Live feed
·
PRReleasevia Quantisnow
Cullinan Therapeutics Inc. logo

Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases

ByQuantisnow·Wall Street's wire, on your screen.
CGEM· Cullinan Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CGEM (Cullinan Therapeutics Inc.) and more on Quantisnow.